Such immune and inflammatory responses could subside, and the residual TSPY-positive tumor cells could resume growth at later stage to large tumors, similar to those without TSPY at 6 weeks (Group-1) post-injection in this mouse model. This evidence concerns the gene TSPY1 and neoplasm.